Business Wire

New Study Evaluates the Use of Masimo PVi ® to Monitor Volume Status in Spontaneously Breathing Hemodialysis Patients

Share

Masimo (NASDAQ: MASI) announced today the findings of a study published in the Turkish Journal of Emergency Medicine in which Drs. Seda Dağar and Hüseyin Uzunosmanoğlu at the Kecioren Training and Research Hospital in Ankara, Turkey investigated the role that noninvasive, continuous Masimo PVi® might play in monitoring volume status and volume changes in spontaneously breathing patients undergoing hemodialysis (HD).1 The researchers found that there was a “strong correlation” between change in PVi and the volume of fluid removed, concluding that “PVi may provide clinicians with useful information for monitoring the volume status in critically ill patients with spontaneous breathing.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210822005033/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Masimo Root® with PVi® (Photo: Business Wire)

More than 100 independent studies have demonstrated the utility of PVi as an indicator of fluid responsiveness.2 Noting that PVi has been studied mostly in mechanically ventilated patients, the researchers sought to investigate its ability to help assess volume changes in spontaneously breathing patients. They enrolled 60 adult patients with end-stage renal disease who received routine HD (during which fluid is removed simultaneously with the removal of waste solutes) and had a median of 3,500 cc of fluid removed during HD. PVi was measured using a Masimo pulse oximetry sensor attached to a Masimo Root® monitor, before and after HD, and changes in PVi were compared to the amount of fluid removed during the session.

The researchers found that mean PVi showed a statistically significant increase after HD, from 20.7% ± 5% to 27.7% ± 6% (p < 0.001). Based on the amount of fluid removed during HD, the change in PVi was statistically significant (p = 0.015) and was strongly correlated to the volume of fluid removed (r = 0.744, p < 0.001).

The researchers concluded, “In the present study, we found that the fluid removed by HD in spontaneously breathing patients caused an increase in PVi and that this increase was strongly correlated with the amount of volume change. Bedside monitoring of PVi, which is a noninvasive, fast, reproducible measurement parameter, may provide the clinicians with useful information for monitoring the volume status and evaluating the effectiveness of volume‑restoration therapy in critically ill patients with spontaneous breathing.”

The accuracy of PVi in predicting fluid responsiveness is variable and influenced by numerous patient, procedure, and device-related factors. PVi measures the variation in the plethysmography amplitude but does not provide measurements of stroke volume or cardiac output. Fluid management decisions should be based on a complete assessment of the patient’s condition and should not be based solely on PVi.

In the U.S., PVi is cleared as a noninvasive, dynamic indicator of fluid responsiveness in select populations of mechanically ventilated adult patients.

@Masimo | #Masimo

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.3 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,4 improve CCHD screening in newborns,5 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.6-9 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,10 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2021-22 U.S. News and World Report Best Hospitals Honor Roll.11 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica™, Halo ION™, UniView®, UniView :60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.

ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

  1. Dağar S, Uzunosmanoğlu H. Assessment of pleth variability index in volume changes during ultrafiltration process. Turkish Journal of Emergency Medicine. 2021;21:111-6.
  2. Published clinical studies on PVi, with varying results and outcomes, can be found on our website at http://www.masimo.com/evidence/pulse-oximetry/pvi. Studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  3. Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
  4. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  5. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  6. Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
  7. Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  8. McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  9. McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
  10. Estimate: Masimo data on file.
  11. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo PVi®. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo PVi, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Masimo
Evan Lamb
949-396-3376
elamb@masimo.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

XY Labs / XYO Network Announces Record Profits for the First Half of 2021 With 2x Growth29.9.2021 01:56:00 CEST | Press release

The XYO Network (Coinbase: $XYO), the geospatial blockchain network, announced today a recent record 2x growth as well as profitability for the first half of 2021. XY Labs generated net income of $3,841,615 in the first half of 2021 through a plethora of disclosed and undisclosed partnerships vs a loss of $1,967,793 in the first half of 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928006178/en/ XYO stated that the number of nodes for the XYO Network had doubled in size over the last three months, noting a promising outlook for the remaining 2021 year and emphasizing a strong recovery from the global lull caused by COVID-19. The company’s announcement shines a light on the constant financial struggle for many crypto-projects, whose main assets like crypto tokens and currencies experience extreme volatility on the decentralized exchanges they trade on. Arie Trouw, one of the project’s founders and CEO of the parent

Spotahome Partners With Homeppl to Offer Tenant Guarantee Solution to Its Landlords Following Rise in Demand for Medium-term Lets29.9.2021 00:01:00 CEST | Press release

Spotahome, the Spanish-based residential platform which manages 200,000 properties in 29 different countries across Europe, has signed an agreement with UK-based tenant due diligence and guarantee firm Homeppl to provide its landlords with a tenant referencing and guarantor service for its medium and long-term lets. With the world opening-up and embracing a post-pandemic life, demand for both medium and long-term rentals has tripled, so being able to approve tenants quickly is imperative. But the risk of tenant fraud remains high, so it is vital that landlords have secure tenant referencing systems in place. Homeppl’s solution combines fraud detection tests, behavioural analysis and financial algorithms, as well as Open Banking data, to assess the true transactional ability of consumers from all over Europe. It has a 0% default rate, and Homeppl is so confident in its referencing solution that it also offers guarantid - a service where it acts as a guarantor for tenants it approves - g

Lunaphore Spatial Biology Technologies to be Featured at Spatial Biology US Conference28.9.2021 21:00:00 CEST | Press release

Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, today announced several presentations featuring the company’s spatial biology technologies at the Spatial Biology US conference taking place virtually September 27 – 30, 2021. Presentations will feature COMET™, Lunaphore’s all-in-one staining and imaging platform for high throughput, hyperplex immunofluorescence, and LabSat®, the company’s compact and open automated tissue staining instrument for immunohistochemistry and multiplex immunofluorescence. PRESENTATION DETAILS How to Optimize a Hyper-Plex Immunostaining Panel in a Fast and Robust Manner Date and time: September 29, 2021 / 4:30 – 5:00 PM ET Speaker: Saska Brajkovic, Head of Application Development, Lunaphore Spatial Proteomics: A Journey to Adopt New Highly Multiplexed Immunohistochemistry Technologies1 Date and time: September 29, 2021 / 2:20 – 2:40 PM ET Speaker: Alexander Klimowicz, Senior Principal Scientist, Boeh

Andersen Global Expands Footprint in Asia; Adds Presence in Four Countries28.9.2021 20:48:00 CEST | Press release

Andersen Global extends its global platform’s eastern coverage through a Collaboration Agreement with tax advisory firm BoardRoom Business Solutions Pte. Ltd., adding 14 locations across Singapore, Malaysia, China and Hong Kong. Founded in 1968, BoardRoom offers a full suite of tax, finance, payroll and corporate secretarial services, providing business solutions and corporate advisory to clients including Fortune 500 multinationals, public companies and privately-owned enterprises. The firm is led by Group CEO Kim Teo and Managing Director of BBS Chester Leong, and operates with 19 Partners and over 800 professionals. “We are pleased to be collaborating with like-minded professionals who invest in their people and promote stewardship to ensure clients receive best-in-class solutions,” Kim said. “Our combined expertise and synergy afford us the opportunity to deliver integrated, independent services in a seamless manner globally.” “BoardRoom provides broad coverage and establishes a st

SKEMA and EADA Create a Double-Degree BBA in Barcelona28.9.2021 19:46:00 CEST | Press release

SKEMA Business School and EADA Business School have signed an agreement to launch a new joint double-degree BBA programme "SKEMA X EADA Global BBA" in Barcelona, where EADA operates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210928006004/en/ Official signing of the partnership between SKEMA and EADA on 20 September 2021 from SKEMA Business School’s Grand Paris Campus. From left to right: Patrice Houdayer, Director of Programmes, International and Student Life, Koke Pursals, Chairman of the Board of Directors of the EADA Foundation, Alice Guilhon, SKEMA’s Dean & Executive President, and Jordi Diaz, EADA’s Dean. (Photo: Business Wire) Through this alliance, SKEMA intends to develop a new European base from EADA's Barcelona campus. EADA will benefit from the presence of SKEMA’s campuses in five continents. At the same time, the two schools also aim to open this new four-year post-baccalaureate programme to candidates from

Zayed Sustainability Prize Announces 30 Finalists During Jury Meeting28.9.2021 19:42:00 CEST | Press release

The Zayed Sustainability Prize, the UAE’s pioneering award for recognising sustainable solutions and humanitarianism, held its Jury meeting to elect winners for its current 2022 cycle, who will be announced during the Prize’s Awards Ceremony at the 2022 Abu Dhabi Sustainability Week (ADSW), this January. A total of 30 finalists were confirmed and are now vying for 10 awards, across the five categories of Health, Food, Energy, Water, and Global High Schools. This year, the Prize received a remarkable 4,000 applications, marking a significant 68.5% increase in entries compared to the previous cycle, while attracting submissions from a record 151 countries, representing over three quarters of the world’s nations. The Prize Jury, comprising former heads of state, government ministers and international business figures, convened through a virtual meeting to review shortlisted submissions identified by the Prize’s Selection Committee in August. In his remarks, H.E. Dr. Sultan bin Ahmed Al Ja

MMIT/Evaluate Acquire Panalgo to Bring Speed and Trust to Pharma Analytics and Decision-Making28.9.2021 17:45:00 CEST | Press release

Managed Markets Insight & Technology (MMIT) and Evaluate, (a Welsh, Carson, Anderson & Stowe and Hg portfolio company)—which joined forces last month to become a $1.6 billion global pharma commercial intelligence provider—announced the acquisition of Panalgo, a premier healthcare data analytics company that serves many of the largest biopharmaceutical, medical device and contract research organizations around the globe. “MMIT/Evaluate and Panalgo share a vision of generating evidence and insights faster, all to help patients get timely access to lifesaving therapies,” said MMIT CEO Mike Gallup. “The addition of Panalgo fits perfectly into our strategy of building a best-in-breed technology- and services-driven healthcare business servicing pharma, biotech and beyond.” With this acquisition, MMIT/Evaluate aim to transform the process of bringing drugs to market. By incorporating Panalgo’s flagship Instant Health Data (IHD) software, MMIT/Evaluate will offer customers an end-to-end comme